Skip to main
BDTX
BDTX logo

BDTX Stock Forecast & Price Target

BDTX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Black Diamond Therapeutics Inc is well-positioned for significant growth due to several anticipated catalysts that could potentially drive its stock price up by over 100%. The company is expected to generate substantial forecasted sales of approximately $500-750 million, particularly if it achieves a favorable overall response rate (ORR) in late 2025, which aligns with prevailing merger and acquisition valuations in the oncology space. Additionally, the strong efficacy of its lead candidate, silevertinib, against a variety of oncogenic mutations could enhance investor confidence and underscore the viability of its therapeutic approach in treating patients with actionable mutations, strategically positioning the company for long-term success.

Bears say

Black Diamond Therapeutics Inc faces a negative outlook primarily due to low investor confidence in its lead drug, silevertinib, particularly in the treatment of EGFRm non-small cell lung cancer (NSCLC), as reflected in its market cap of approximately $230 million. Concerns are amplified by the potential underdosing of silevertinib and the risk associated with phase 3 trial results, which may not meet efficacy expectations if the tested population proves less sensitive to treatment. Additionally, investor disappointment following recent clinical updates further complicates the company’s prospects and diminishes confidence in its competitive position within the oncology market.

BDTX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Black Diamond Therapeutics (BDTX) Forecast

Analysts have given BDTX a Strong Buy based on their latest research and market trends.

According to 5 analysts, BDTX has a Strong Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Black Diamond Therapeutics (BDTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.